Abstract
Diabetes is one of the major noncommunicable diseases found worldwide. Different researchers have reported the predicted and observed prevalence of diabetes and the number of people with diabetes over different years in China and in other countries. This review provides a new insight into the growing epidemic of diabetes in recent decades and in the coming future by comparing projected and observed prevailing trends of this disease reported in the international literature. The review found that the projected burden of diabetes for China in each time point from 2000 to 2030 underestimated the epidemic of diabetes in terms of the prevalence and the total number of people with the disease. Based on a recent Chinese national survey, the observed prevalence and the total number of people with diabetes in 2008 (9.7% and 92.4 million, respectively) were remarkably higher than that expected for 2009 or 2010 (3.9% and 53.1 million for 2009, and 4.5% and 43.2 million for 2010).The observed 2008 figures were even much higher than the projected prevalence and the number of people with diabetes for 2030. The tendency to underestimate future diabetes epidemics also occurs in many other countries, especially those characterized by low and middle incomes.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Saundby R. Diabetes mellitus among the Chinese. Br Med J. 1908;1:116.
National Diabetes Research Group. A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China (author’s transl). Zhonghua Nei Ke Za Zhi. 1981;11:678–83.
Hu YH, Li GW, Pan XR. Incidence of NIDDM in Daqing and forecasting of NIDDM in China in 21st century. Zhonghua Nei Ke Za Zhi. 1993;32(3):173–5.
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. This paper predicted the worldwide prevalence rates and number of patients with diabetes in 2010 and 2030.
Pan XR, Yang WY, Li GW, Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care. 1997;20(11):1664–9.
Wang K, Li T, Xiang H, Liu Z, Bai J, Feng J, et al. Study on the epidemiological characteristics of diabetes mellitus and IGT in China. Zhong Guo Liu Xing Bing Xue Za Zhi. 1998;19(5):282–5.
Pan C. Diabetes care in China: meeting the challenge. World Hosp Health Serv. 2005;41(3):29–30. 2.
• Pan C, Shang S, Kirch W, Thoenes M. Burden of diabetes in the adult Chinese population: a systematic literature review and future projections. Int J Gen Med. 2010;3:173–9. This paper estimated and predicted the prevalence rates of diabetes in China for 2009 and 2016.
Liu S, Wang W, Zhang J, He Y, Yao C, Zeng Z, et al. Prevalence of diabetes and impaired fasting glucose in Chinese adults, China National Nutrition and Health Survey, 2002. Prev Chronic Dis. 2011;8(1):A13.
Department of Population, Social, Science and Technology Statistics National Bureau of Statistics of China. China population statistics yearbook. Beijing: China Statistics Press; 2003.
• Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101. This is the most recent survey for prevalence of diabetes and prediabetes in China.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.
Jia WP, Pang C, Chen L, Bao YQ, Lu JX, Lu HJ, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50(2):286–92.
Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, et al. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovasc Ther. 2010;28(2):124–32.
Liu J, Grundy SM, Wang W, Smith Jr SC, Vega GL, Wu Z, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J. 2007;153(4):552–8.
International Diabetes Federation. Diabetes atlas, 3rd edn. Diabetes and Impaired Glucose Tolerance. 2006.
Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–32.
Chen CM. Overview of obesity in Mainland China. Obes Rev. 2008;9 Suppl 1:14–21.
Fu P, Man Q, Zhang J, Wang C. Epidemiological study on diabetes mellitus in Chinese children and adolescents at the age of 5 to 17 years. Wei Sheng Yan Jiu. 2007;36(6):722–4.
Liu W, Lin R, Liu A, Du L, Chen Q. Prevalence and association between obesity and metabolic syndrome among Chinese elementary school children: a school-based survey. BMC Publ Health. 2010;10:780.
• WHO. World Health Organization. 2008. http://apps.who.int/ghodata/?vid=2469. 2008. This website provided the most recent data for global prevalence rates of diabetes from the members of WHO.
WHO. Diabetes Fact Sheet No. 312. 2011. http://www.who.int/mediacentre/factsheets/fs312/en/.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, D., Zhao, F., Li, Y. et al. Projected and Observed Diabetes Epidemics in China and Beyond. Curr Cardiol Rep 14, 106–111 (2012). https://doi.org/10.1007/s11886-011-0227-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11886-011-0227-9